D
David C. Fajgenbaum
Researcher at University of Pennsylvania
Publications - 110
Citations - 4246
David C. Fajgenbaum is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Medicine & Castleman disease. The author has an hindex of 19, co-authored 76 publications receiving 2175 citations. Previous affiliations of David C. Fajgenbaum include Leonard Davis Institute of Health Economics & Hospital of the University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Cytokine Storm.
David C. Fajgenbaum,Carl H. June +1 more
TL;DR: From the Department of Medicine, Division of Translational Medicine and Human Genetics, Center for Cytokine Storm Treatment and Laboratory, and the Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia.
Journal ArticleDOI
International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease
David C. Fajgenbaum,Thomas S. Uldrick,Adam Bagg,Dale Frank,David Wu,Gordan Srkalovic,David Simpson,Amy Y. Liu,David M. Menke,Shanmuganathan Chandrakasan,Mary Jo Lechowicz,Raymond S.M. Wong,Sheila K Pierson,Michele Paessler,Jean François Rossi,Makoto Ide,Jason R. Ruth,Michael P. Croglio,Alexander Suarez,Vera P. Krymskaya,Amy Chadburn,Gisele W. B. Colleoni,Sunita D. Nasta,Raj Jayanthan,Christopher S. Nabel,Corey Casper,Angela Dispenzieri,Alexander Fosså,Dermot Kelleher,Razelle Kurzrock,Peter M. Voorhees,Ahmet Dogan,Kazuyuki Yoshizaki,Frits van Rhee,Eric Oksenhendler,Elaine S. Jaffe,Kojo S.J. Elenitoba-Johnson,Megan S. Lim +37 more
TL;DR: The proposed consensus criteria will facilitate consistent diagnosis, appropriate treatment, and collaborative research and exclude infectious, malignant, and autoimmune disorders that can mimic iMCD.
Journal ArticleDOI
HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.
TL;DR: It is proposed that 1 or more of the following 3 candidate processes may drive iMCD hypercytokinemia: systemic inflammatory disease mechanisms via autoantibodies or inflammatory gene mutations, paraneoplastic syndrome mechanisms via ectopic cytokine secretion, and/or a non-HHV-8 virus.
Journal ArticleDOI
Idiopathic multicentric Castleman's disease: a systematic literature review
Amy Y. Liu,Christopher S. Nabel,Brian S. Finkelman,Jason R. Ruth,Razelle Kurzrock,Frits van Rhee,Vera P. Krymskaya,Dermot Kelleher,Arthur H. Rubenstein,David C. Fajgenbaum +9 more
TL;DR: A systematic review provides comprehensive information about clinical features, treatment, and outcomes of idiopathic multicentric Castleman's disease, which accounts for at least 33% of all cases of multicentric Castellan's disease.
Journal ArticleDOI
Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease
Noriko Iwaki,David C. Fajgenbaum,Christopher S. Nabel,Yuka Gion,Eisei Kondo,Mitsuhiro Kawano,Taro Masunari,Isao Yoshida,Hiroshi Moro,Koji Nikkuni,Kazue Takai,Kosei Matsue,Mitsutoshi Kurosawa,Masao Hagihara,Akio Saito,Masataka Okamoto,Kenji Yokota,Shinichiro Hiraiwa,Naoya Nakamura,Shinji Nakao,Tadashi Yoshino,Yasuharu Sato +21 more
TL;DR: TAFRO syndrome is a unique subtype of iMCD that demonstrates characteristic clinicopathological findings and further study to clarify prognosis, pathophysiology, and appropriate treatment is needed.